Isomorphic Labs is a AI drug discovery platform that was spun off from Google DeepMind in 2021. The company stated that it has raised $5 billion in its Series C financing, with the goal of advancing its drug candidates into clinical trials.
This round of financing was co-led by Greenoaks and Sequoia Capital, with new investor Andreessen Horowitz and other investors also participating. All of the company's existing supporters also participated in this round of investment, including the venture capital departments GV and Capital G under Alphabet, as well as Thrive Capital, MGX, Temasek, and the British sovereign AI fund.
Isomorphic Labs is building a AI drug design engine that utilizes a series of AI simulation models to explore different areas of chemistry, aiding the company in drug design. The company stated that its projects, based on the DeepMind breakthrough protein folding AI model AlphaFold, have achieved "positive preclinical results" in oncology and immunology. The laboratory has also established collaborations with pharmaceutical giants such as Eli Lilly, Novartis, and Johnson & Johnson.
Following the $2.1 billion Series B financing completed in May of this year, this new round of funding will be used to continue developing its drug design engine and expand it to more types of drugs.
This is also the first financing since Isomorphic's founder and CEO, Demis Hassabis, left his position as the head of DeepMind to focus on drug discovery; he also serves as the chairman of DeepMind at the same time. Hassabis and the then DeepMind director, John Jumper, won the Nobel Prize in Chemistry for their work on AlphaFold. AlphaFold is a system that can predict the three-dimensional structure of proteins based solely on their genetic sequences.
Isomorphic has not disclosed a new valuation. Bloomberg reported earlier this month that the laboratory is seeking financing with a valuation of $50 billion.











